AIMS: The aims of this investigation were to evaluate the efficacy of regular inhaled @entity2715 in the control of symptoms and lung function with non-asthmatic smoking related @entity3885 and to evaluate the relationship between clinical responses to a short course of oral @entity229 and longer term outcomes using inhaled @entity134 . METHODS: The study was a randomised, double blind, placebo controlled, crossover investigation in 18 @entity1 . The active treatment was inhaled @entity2715 1000 micrograms given twice daily for three months by metered dose inhaler. At the end of each treatment period, @entity1 received oral @entity229 30 mg/day for ten days. The two treatment phases were separated by a one month washout interval. Peak flow rates, symptom scores and "rescue" bronchodilator use were recorded twice daily. Lung function (FEV1, FVC and lung volumes) and @entity2488 (PC20 @entity2710 ) were measured at monthly visits. The number of exacerbations requiring intervention therapy were also recorded. RESULTS: There were no consistent benefits attributable to @entity2715 . Lung function was not significantly better as a result of active treatment. Sputum production improved but other symptom scores were similar during active and placebo therapy. Three @entity1 exhibited an increase in FEV1 of 15% or more during active treatment but did not do so when oral @entity229 was administered immediately after the period of placebo treatment. A further three @entity1 showed an improvement in FEV1 of 15% or more with oral @entity229 but failed to improve during treatment with inhaled @entity2715 . The predictive value of the "trial of @entity134 " was 0% and 81.3% for positive and negative outcomes respectively. CONCLUSIONS: Our results indicate that in non-asthmatic @entity1030 inhaled corticosteroid fails to achieve significant improvements in either lung function or symptoms. The response to a "trial of @entity134 " using oral @entity229 is not clinically helpful in selecting the small number of @entity1 who may subsequently benefit from this form of therapy.

The efficacy of inhaled corticosteroids in the management of non asthmatic chronic XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2715 :: ('MESH:D001507', 'Chemical') :: ['beclomethasone'] @entity2488 :: ('MESH:D001982', 'Disease') :: ['bronchial hyperresponsiveness'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity3885 :: ('MESH:D008173', 'Disease') :: ['obstructive pulmonary disease'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic obstructive pulmonary disease'] @entity2710 :: ('MESH:D016210', 'Chemical') :: ['methacholine']
@entity1030 :: (MESH:D029424,Disease) :: ['airflow obstruction']
